Fred E Cohen
CIK 1339358 · last filed 2026-06-16
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
GHDX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 1445
FORT WORTH, TX 76102
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CDNA | Director | 165,060 | $69.10 | $11.41M | $0 | 34 | 2026-06-16 |
| NTLA | Director | 216,653 | $11.26 | $2.44M | $1.40M | 12 | 2026-06-10 |
| KYTX | Director | 4,545,651 | $5.27 | $23.96M | $0 | 3 | 2026-05-29 |
| URGN | Director | 84,339 | $34.04 | $2.87M | $0 | 8 | 2024-08-08 |
| PGNY | Director | 22,693 | $28.13 | $638.4K | $0 | 6 | 2024-05-28 |
| VCYT | Director | 10,000 | $48.20 | $482.0K | -$1.07M | 9 | 2020-10-20 |
| GENOMIC HEALTH INC (GHDX) Delisted | Director | 75,188 | — | — | -$3.63M | 57 | 2019-10-03 |
| TNDM | Director | — | $18.90 | — | $0 | 7 | 2018-11-19 |
| BCRX | Director | 173,660 | $7.88 | $1.37M | -$294.0K | 19 | 2018-06-22 |
| Roka BioScience, Inc. (ROKA) Delisted | Director | — | — | — | $0 | 3 | 2017-06-30 |
| FIVE PRIME THERAPEUTICS, INC. (XLRN) Delisted | Director | — | $178.75 | — | $0 | 2 | 2017-05-12 |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Director | 24,807 | $38.00 | $942.7K | $0 | 3 | 2016-01-13 |
Recent Filings · Page 2 of 17
165 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-06-18 | CDNA | Grant (A) | +10,570 | $0 | EDGAR |
| 2024-06-14 | NTLA | Grant (A) | +7,737 | $0 | EDGAR |
| 2024-05-28 | PGNY | Grant (A) | +6,176 | $0 | EDGAR |
| 2024-02-14 | KYTX | Conv (C) | +4,523,924 | $0 | EDGAR |
| 2023-09-08 | URGN | Grant (A) | — | $0 | EDGAR |
| 2023-07-28 | URGN | Grant (A) | +69,339 | $661.5K | EDGAR |
| 2023-06-21 | CDNA | Grant (A) | +18,844 | $0 | EDGAR |
| 2023-06-16 | NTLA | Grant (A) | +4,425 | $0 | EDGAR |
| 2023-05-26 | PGNY | Grant (A) | +4,385 | $0 | EDGAR |
| 2023-01-09 | CDNA | Grant (A) | +1,062 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.